Abliva is a Swedish drug development company based in Lund. It is a public company focused on developing treatments for a rare group of largely genetic disorders known as primary mitochondrial diseases. Its lead product KL 1333 is intended for the treatment of MELAS and MELAS-like syndromes. The product is in clinical development.

Year of investment
2020

Sector
Drug development

Location
Stockholm, Sweden

Website
http://abliva.com/

Leave a Reply

Your email address will not be published. Required fields are marked *